Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DNA X, Inc.SONM · Entity 8261 | Director | November 12, 2021 | November 16, 2021 |
| Globalstar, Inc.GSAT · Entity 3507 | Director | March 01, 2018 | May 10, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DNA X, Inc.
Report date November 12, 2021 · Filed November 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,220 |
Reported balance
After 2021-11-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-11-12 · Grant · Acquired 27,906 · Balance 40,220 F1: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of the Issuer or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2: The amount of securities reported in this Form 4 as beneficially owned by the Reporting Person reflects adjustments made in connection with a 1-for-10 reverse stock split of the Issuer's common stock on September 15, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of the Issuer or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.
F2: The amount of securities reported in this Form 4 as beneficially owned by the Reporting Person reflects adjustments made in connection with a 1-for-10 reverse stock split of the Issuer's common stock on September 15, 2021.
Globalstar, Inc.
Report date March 01, 2018 · Filed May 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | Direct | 155,500 |
Reported balance
After 2018-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-03-01 · Grant · Acquired 75,000 · Balance 155,500 F1: Award under 2006 Equity Incentive Plan. Award vests on December 31, 2018. |
| Voting Common StockSEC Table I · non-derivative | Direct | 305,500 |
Reported balance
After 2018-03-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-03-01 · Grant · Acquired 150,000 · Balance 305,500 F2: Award under 2006 Equity Incentive Plan. Award vests as to one-third on each of February 28, 2019, 2020 and 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2027-02-27 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2018-03-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 100,000 F3: Options vested and will vest as to one-third each on February 27, 2017, 2018 and 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2021-02-03 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2018-03-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 200,000 F4: Options are exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2026-05-16 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2018-03-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 100,000 F4: Options are exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2023-08-08 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2018-03-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 200,000 F4: Options are exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Award under 2006 Equity Incentive Plan. Award vests on December 31, 2018.
F2: Award under 2006 Equity Incentive Plan. Award vests as to one-third on each of February 28, 2019, 2020 and 2021.
F3: Options vested and will vest as to one-third each on February 27, 2017, 2018 and 2019.
F4: Options are exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2021 Filed Nov 16, 2021 21:33 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 27,906 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044818 · doc4.xml · nonDerivative · entry 1 Kneuer John · CIK 0001512329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,220 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of the Issuer or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: The amount of securities reported in this Form 4 as beneficially owned by the Reporting Person reflects adjustments made in connection with a 1-for-10 reverse stock split of the Issuer's common stock on September 15, 2021. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:10 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 104,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035995 · doc4.xml · nonDerivative · entry 1 Kneuer John · CIK 0001512329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,147 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning on June 9, 2020. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 23:10 UTC | DNA X, Inc. SONM · Entity 8261 | GrantStock Option (right to buy) · Derivative | 43,928 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001209191-20-000418 · doc4.xml · derivative · entry 1 Kneuer John · CIK 0001512329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,928 Underlying: Common Stock · 43,928 shares Expires 2029-12-29 F1 · derivative.exercise_date: The Options shall vest: (a) with respect to 75% of the shares at such time as the price of the Company's Common Stock equals or exceeds $5.00 per share, (b) with respect to 15% of the shares at such time as the price of the Company's Common Stock equals or exceeds $7.00 per share; and (c) with respect to 10% of the shares at such time as the price of the Company's Common Stock equals or exceeds $8.00 per share, provided that all shares shall vest in full upon consummation of a change in control transaction. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 23:45 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-056820 · doc4.xml · nonDerivative · entry 2 Kneuer John · CIK 0001512329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,147 F2 · shares: Represents the grant of restricted stock units (the "RSU") that vest in three equal annual installments beginning on May 9, 2019, subject to continued service. The RSU is the initial equity grant to which each non-employee director is entitled for service on the Issuer's board of directors pursuant to the non-employee director compensation policy that has been approved by the compensation committee of the Issuer's board of directors. The number of shares subject to the RSU was determined by reference to the price of the Issuer's common stock in its initial public offering, or $11 per share. Read SEC document |
| June 10, 2019 Filed Jun 10, 2019 22:41 UTC | DNA X, Inc. SONM · Entity 8261 | PurchaseCommon Stock | 3,100 | $16.99 | $52,669.00 |
DisclosureSEC source: 0001209191-19-035969 · doc4.xml · nonDerivative · entry 2 Kneuer John · CIK 0001512329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,147 Read SEC document |
| June 10, 2019 Filed Jun 10, 2019 22:41 UTC | DNA X, Inc. SONM · Entity 8261 | PurchaseCommon Stock | 47 | $16.25 | $763.75 |
DisclosureSEC source: 0001209191-19-035969 · doc4.xml · nonDerivative · entry 1 Kneuer John · CIK 0001512329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47 Read SEC document |
| May 10, 2019 Filed Nov 15, 2019 23:45 UTC | DNA X, Inc. SONM · Entity 8261 | PurchaseCommon Stock | 1,000 | $11.00 | $11,000.00 |
DisclosureSEC source: 0001209191-19-056820 · doc4.xml · nonDerivative · entry 1 Kneuer John · CIK 0001512329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,147 F1 · shares: These shares were omitted from the total amount of securities beneficially owned reported in Table I, Column 5 of the Reporting Person's Form 4 filed on June 10, 2019. Read SEC document |
| March 01, 2018 Filed May 10, 2018 19:35 UTC | Globalstar, Inc. GSAT · Entity 3507 | GrantVoting Common Stock | 150,000 | $0.98 | $147,570.00 |
DisclosureSEC source: 0001366868-18-000038 · wf-form4_152598088286680.xml · nonDerivative · entry 2 Kneuer John · CIK 0001512329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,500 F2 · security: Award under 2006 Equity Incentive Plan. Award vests as to one-third on each of February 28, 2019, 2020 and 2021. Read SEC document |
| March 01, 2018 Filed May 10, 2018 19:35 UTC | Globalstar, Inc. GSAT · Entity 3507 | GrantVoting Common Stock | 75,000 | $0.98 | $73,785.00 |
DisclosureSEC source: 0001366868-18-000038 · wf-form4_152598088286680.xml · nonDerivative · entry 1 Kneuer John · CIK 0001512329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,500 F1 · security: Award under 2006 Equity Incentive Plan. Award vests on December 31, 2018. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:20 UTC | Globalstar, Inc. GSAT · Entity 3507 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001366868-17-000021 · wf-form4_148841043923702.xml · derivative · entry 2 Kneuer John · CIK 0001512329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Voting Common Stock · 100,000 shares Expires 2027-02-27 F1 · derivative.exercise_date: Options vest as to one-third each on February 27, 2017, 2018 and 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.